Download BIOGRAPHICAL SKETCH

Principal Investigator/Program Director: Davie, Jim, R.
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
James (Jim) R. Davie
Professor
eRA COMMONS USER NAME
JRDAVIE
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
DEGREE
(if applicable)
YEAR(s)
University of British Columbia, Vancouver, CA
B.Sc.
1975
Biochemistry
University of British Columbia, Vancouver, CA
Oregon State University, Corvallis, Oregon
Ph.D.
Postdoctoral
1979
1983
Biochemistry
Biochemistry
INSTITUTION AND LOCATION
A.
FIELD OF STUDY
Personal Statement
Dr. James Davie is a recognized leader with over thirty years of experience in the field of chromatin dynamics.
He has been responsible for several of the seminal findings in this rapidly expanding field. He has published
over 200 original articles in peer reviewed journals including the prestigious journals, Cell, Nature, and
Science. These studies have been cited more than 13,200 times, generating a most impressive H-index of 55.
His research program explores the role of chromatin modifiers in regulating gene expression. His long-term
interest in the chromatin modifiers, histone deacetylases and histone kinases, and histone modifications has
produced many landmark papers. His early work reported that butyrate was a histone deacetylase inhibitor
which stopped the growth of cancer cells. These studies set the foundation for development of histone
deacetylase inhibitor drugs that are now used in the clinic for treatment of cancer.
B. Positions and Honors.
Positions and Employment
1983-1988
Assistant Professor, Department of Biochemistry and Molecular Biology, Univ. Manitoba
1988-1992
Associate Professor, Department of Biochemistry and Molecular Biology, Univ. Manitoba
1992-present Professor with tenure, Department of Biochemistry and Medical Genetics, Univ. Manitoba
1998-2000
Senior Scientist and Associate Director, Manitoba Institute of Cell Biology
1998-present Senior Scientist, Research Institute of Oncology & Hematology (RIOH) / CancerCare Manitoba
2000-2008
Director, Manitoba Institute of Cell Biology
2000-2008
Provincial Director (research), CancerCare Manitoba
2009-2010
Executive Director, Manitoba Health Research Council
2009-2015
Leader, Terry Fox Research Institute Prairie Node
2010-2013
Scientific Director, Manitoba Health Research Council
2011-present Member, Children’s Hospital Research Institute of Manitoba (CHRIM) (formerly Manitoba
Institute of Child Health (MICH))
Honors
1979-1982
1984-1985
1985
1985-1990
1991-1996
1997-2002
2000-2008
2004-2018
Medical Research Council of Canada (MRC) Postdoctoral Fellowship
Manitoba Health Research Council Scholarship
National Cancer Institute of Canada Senior Scientist Award
MRC Scholarship
MRC Scientist Award
Canadian Institutes of Health Senior Scientist Award
Margaret A. Sellers Chair
Canada Research Chair, Tier I in Chromatin Dynamics
PHS 398/2590 (Rev. 09/04)
Page
1
Biographical Sketch Format Page
Principal Investigator/Program Director: Davie, Jim, R.
US Study Section Memberships
1993
NIH NIAMS AD HOC Review Committee
2001
NIH NIAMS AD HOC Review Committee
2002-2008 National Cancer Institute AD HOC Review Committees
2005, 2006 DOD Breast Cancer Research Review Panel
Canadian Grant Review Panels
2004Member, CFI New Opportunities Fund, College of Reviewers
2004Member, CRC, College of Reviewers
2008-2011
Member, Scientific and Medical Advisory Committee, Prostate Cancer Canada
2010-2012
Member, Grant Review Committee Biochemistry and Molecular Biology panel B, CIHR
2010
Member, Ontario Research Fund-Global Leadership in Genomics and Life Sciences Cancer &
Stem Cells peer-review panel
2010
Member, Alberta Cancer Research Institute Grant Review Committee
2011
Member, Grant Review Panel D, CCSRI
Editorial Board Memberships
1995-present
Journal of Cellular Biochemistry, Associate Editor
1997-present
Molecular Biology Reports, Associate Editor
1997-2002; 2006-2011 Journal of Biological Chemistry, Editorial Board member
1999-present
Biochemistry and Cellular Biology, Editor
2008-present
International Journal of Cell Biology, Editorial Board member
C. Selected peer-reviewed publications (past five years).
H-index, 55 (Publications selected from 200 peer-reviewed publications)
1. Healy, S, Khan, D. and Davie, J.R. (2011) Gene expression regulation through 14-3-3 interactions with
histones and HDACs. Discovery Medicine. 11, 349-358.
2. Pérez-Cadahía, B., Drobic, B., Espino, P.M. and Davie, J.R. (2011) Essential role of mitogen and stress
activated kinase 1 activity in immediate-early gene expression and RAS-mediated phenotype. J. Biol.
Chem. 286, 42-49.
3. Khan, D.H., Jahan, S. and Davie, J.R. (2012) Pre-mRNA splicing: Role in epigenetics and implications in
disease. Advances in Biol. Regul. 52, 377-388.
4. Delcuve, G.P, Khan, D.H. and Davie, J.R. (2012) Roles of histone deacetylases (HDACs) in epigenetic
regulation: emerging paradigms from studies with inhibitors. Clinical Epigenetics 4, 5, 1-13.
5. Sundar, I.K., Chung, S., Hwang, J.W., Lapek, J.D., Bulger, M., Friedman, A.E., Yao, H., Davie, J.R., and
Rahman, I. (2012) Mitogen- and stress-activated kinase 1 (MSK1) regulates cigarette smoke induced
histone modifications on NF-κB-dependent genes. PLoS One 7, e3137
6. Gang, H., Shaw, J., Dhingra, R., Davie, J.R., and Kirshenbaum, L.A. (2013) Epigenetic regulation of
canonical TNFα pathway by HDAC1 determines survival of cardiac myocytes. Am J Physiol Heart Circ
Physiol. 304, H1662-9
7. Khan, D.S., He, S., Yu, J., Winter, S., Seiser, C. and Davie, J.R. (2013) Protein kianse CK2 regulates the
dimerization of HDAC1 and HDAC2 during mitosis. J. Biol. Chem. 288, 16518-28.
8. Khan, D. and Davie, J.R. (2013) Histone deacetylase inhibitors block the nucleosomal response and
induction of immediate early genes. FEBS Lett. 587, 1510-7
9. Khan, P., Drobic, B., Pérez-Cadahía, B., Healy, S. and Davie, J.R. (2013) Mitogen- and stress-activated
protein kinases 1 and 2 are required for maximal trefoil factor 1 induction. PLoS One 13;8(5):e63189
PHS 398/2590 (Rev. 09/04)
Page
2
Continuation Format Page
Principal Investigator/Program Director: Davie, Jim, R.
10. Thompson, L.L., Guppy, B.J., Sawchuk, L., Davie, J.R., and McManus, K.J. (2013) Regulation of
chromatin structure via histone post-translational modification and the link to carcinogenesis. Cancer and
Metastasis Reviews 32, 363-376.
11. He, S., Khan, D.H., Winter, S., Seiser, C., and Davie, J.R. (2013) Dynamic distribution of HDAC1 and
HDAC2 during mitosis: association with F-actin. J Cell Physiol 228, 1525-35.
12. Delcuve, G.P., Khan, D.H., and Davie, J.R. (2013) Targeting class I histone deacetylases in cancer
therapy. Exp Opin Ther Targets 17, 29-41.
13. Healy, S, Khan, P. and Davie, J.R. (2013) Immediate early response genes and cell transformation.
Pharmacol Thers 137, 64-77.
14. Khan, D.H., Gonzalez, C., Cooper, C., Sun, J.M., Chen, H.Y., Healy, S., Xu, W., Smith, K.T., Workman,
J.L., Leygue, E., and Davie, J.R. (2014) RNA-dependent dynamic histone acetylation regulates MCL1
alternative splicing. Nucleic Acids Res., 42, 1656-70.
15. Liyanage VRB, Jarmasz J, Murugeshan N, Del Bigio MR, Rastegar M, and Davie JR. DNA
Modifications:Function and Applications in Normal and Disease States. Biology. 2014; 22;3 (4):670-723.
doi:10.3390/biology3040670.
16. Liyanage VRB, Zachariah RM, Davie JR, and Rastegar M. Ethanol Deregulates Mecp2/MeCP2 in
Differentiating Neural Stem Cells via Interplay Between 5-methylcytosine and 5-hydroxymethylcytosine at
the Mecp2 Regulatory Elements. Experimental Neurology 2015; 265 102-117. Doi:
10.1016/j.expneurol.2015.01.06
D. Research Support
Ongoing Research Support

CIHR (TEC 128094) (2013-2018) Team Leader (Co-PIs: M Rastegar, A Fainsod, B Elias, M Del Bigio, and
G Hicks) Discovering the epigenetic signatures associated with fetal alcohol spectrum disorders.
$285,000 per annum - ranked 2nd in competition.

Canadian Breast Cancer Foundation (2014-2017). TNF alpha gene signature in triple-negative breast
cancer cells. $124,000 per annum - ranked 5th out of 51 in competition.

CCSRI Innovation grant (2014-2016). Nuclear RNA and PRDX1. $98,000 per annum.

CancerCare Manitoba Foundation (2014-2016). Nucleosomal response pathway and transcriptional
programming, $60,000 per annum – ranked 1st in competition.

Children’s Hospital Research Institute of Manitoba (formerly MICH) (2014-2016).
Ubiquitin carboxyl-terminal esterase L1 (UCHL1) - role in regulating gene expression in the pancreatic beta
cells with Christine Doucette. $40,000.

CIIFAC (2014-2016) (Co-PI: M. Del Bigio) The Effects of Gestational Alcohol Exposure on the
Epigenetics of the Developing Brain. $10,000 for two years.
PHS 398/2590 (Rev. 09/04)
Page
3
Continuation Format Page
Principal Investigator/Program Director: Davie, Jim, R.
Completed Research Support

Canadian Breast Cancer Foundation (2012-2015). Histone deacetylase inhibitors and alternative RNA
splicing. $120,888 per annum.

CIHR Catalyst grant (2013-2014) (Co-PI: M Rastegar) Investigating the cell type-specific regulatory role of
ethanol on MeCP2 expression. $100,000 per annum.

Canadian Breast Cancer Foundation (2011-2014). Role of peroxiredoxin phosphorylation in estrogen
receptor negative breast cancer. $111,859 per annum - ranked 1st in competition
PHS 398/2590 (Rev. 09/04)
Page
4
Continuation Format Page